Introduction I read with interest the article by Pan et al. (2025) on HSK21542 (Anrikefon) for managing CKD-associated pruritus (CKD-aP) in haemodialysis patients. This Phase II trial addresses an important unmet need for patients that suffer from CKD-aP. However, I have identified material errors in the authors’ interpretation of their results, as well as some uncontextualized comparisons. Here I highlight these, in the interest of scientific dialogue.
Steven Fishbane
Cold Spring Harbor
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Steven
Contact Steven, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack